Long term follow up of treatment with ibrutinib and rituximab (IR) in patients with high-risk Chronic Lymphocytic Leukemia (CLL)

BACKGROUND: Ibrutinib is an active therapy with acceptable safety profile for patients with CLL, including high-risk patients with del17p or with TP53 mutations. Ibrutinib is broadly indicated for the treatment of patients with chronic lymphocytic leukemia and specifically including those with 17p d...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Clin Cancer Res
Päätekijät: Jain, Preetesh, Keating, Michael, Wierda, William, Sivina, Mariela, Thompson, Philip A., Ferrajoli, Alessandra, Estrov, Zeev, Kantarjian, Hagop, O'Brien, Susan, Burger, Jan A.
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: 2016
Aiheet:
Article
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC5397369/
https://ncbi.nlm.nih.gov/pubmed/27797975
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-16-1948
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia